by Roshan Yoganathan | Apr 17, 2014
Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the...
by Mark Curtis | Mar 11, 2014
. Welcome to your update from the clinic for the month of February! OncoMed is the leader in news this month with various Phase 1b trials for its cancer stem cell-targeting fusion protein. Immunocellular Therapeutics and StemCells Inc. file orphan drug designations...
by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
by Mark Curtis | Jan 7, 2014
. Welcome to your Update from the Clinic for the month of December. Athersys and NeoStem both confirm completion of enrollment for phase 2 studies while bluebird bio announces the first patient transplanted in its phase 1/2 study of HGB-205 in patients with...
by Paul Krzyzanowski | Dec 16, 2013
> This is part three of an interview series with Michael West, CEO of BioTime. Read parts one and two. The prospects for BioTime and other companies that operate in the tissue engineering and cell therapy market are good. The industry is growing by about 18% per...
by Mark Curtis | Nov 27, 2013
. Welcome to the regenerative medicine deal review for the month of November. Cytori Therapeutics and Lorem Vascular have teamed up to catalyze the commercialization of Cytori cell therapies using its proprietary Celution® System in Asia. There was also a notable deal...
Comments